Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.

Anticancer research - 1 Jun 2020

Moon Seong Mi, Kim Ji-Ho, Kim Seong Keun, Kim Seonwoo, Kwon Hyuk-Jung, Bae Jin-Sik, Lee Sunghoon, Lee Hye Seon, Choi Mi-Young, Jeon Byung Hee, Jeong Byeong-Ho, Lee Kyungjong, Kim Hong Kwan, Kim Jhingook, Um Sang-Won

Abstract excerpt

BACKGROUND/AIM: Although it has been suggested that circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) might be used in a complementary manner in lung cancer diagnosis, limited confirmatory data are available. In this prospective study, we evaluated the diagnostic performance of each assay separately and in combination. PATIENTS AND METHODS: From March 2018 to January 2019, patients with suspected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Circulating Tumor DNA

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Disease Susceptibility

Share to DNA, Neoplasm

Share to Liquid Biopsy

Share to Lung Neoplasms

Share to Neoplasm Staging

Share to Neoplastic Cells, Circulating

Source

Identifiers

PMID: 32487642
DOI: 10.21873/anticanres.14329

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Utility of Combined Circulating Tumor Cell and Circulating Tumor DNA Assays for Diagnosis of Primary Lung Cancer.PMID 32487642Read ↗

Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer.Semantic proximity Read ↗

Clinical Application of Next-Generation Sequencing of Plasma Cell-Free DNA for Genotyping Untreated Advanced Non-Small Cell Lung CancerSemantic proximity Read ↗

The Utility of ctDNA in Lung Cancer Clinical Research and Practice: A Systematic Review and Meta-Analysis of Clinical Studies.Semantic proximity Read ↗

Clinical validity of oncogenic driver genes detected from circulating tumor DNA in the blood of lung cancer patientsSemantic proximity Read ↗

Resectable lung lesions malignancy assessment and cancer detection by ultra-deep sequencing of targeted gene mutations in plasma cell-free DNASemantic proximity Read ↗

Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing.Semantic proximity Read ↗

A comparative study on ctDNA and tumor DNA mutations in lung cancer and benign cases with a high number of CTCs and CTECs.Semantic proximity Read ↗

Circulating EGFR Mutations in Patients with Lung Adenocarcinoma by Circulating Tumor Cell Isolation Systems: A Concordance Study.Semantic proximity Read ↗

ctDNA from body fluids is an adequate source for EGFR biomarker testing in advanced lung adenocarcinoma.Semantic proximity Read ↗

Circulating cell-free DNA has a high degree of specificity to detect exon 19 deletions and the single-point substitution mutation L858R in non-small cell lung cancerSemantic proximity Read ↗

Sputum cell-free DNA for detection of alterations of multiple driver genes in lung adenocarcinoma.Semantic proximity Read ↗

Circulating tumor DNA is effective for the detection of EGFR mutation in non-small cell lung cancer: a meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.